Globus Medical vs Insulet

Globus Medical (GMED), health care, and Insulet (PODD), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

Insulet is worth $10.1B on the stock market and Globus Medical $9.3B: Insulet is valued at 9% more. Globus Medical trades at 17.2 times earnings and Insulet at 23.7; operating margins in their latest fiscal years were 16.3% and 17.5%. Over the past year Globus Medical's share price has moved -15.5% and Insulet's -56.4%.

Key facts

Globus Medical market value
$9.3B
Insulet market value
$10.1B
Globus Medical P/E
17.2
Insulet P/E
23.7
Globus Medical revenue
$2.9BFY to 2025-12-31
Insulet revenue
$2.7BFY to 2025-12-31
Superinvestors holding both
0

Market values as of .

Globus Medical vs Insulet: every measure side by side
Measure Globus Medical Insulet
SectorHealth CareHealth Care
Country United States United States
Fiscal year ends2025-12-312025-12-31
Size
Market cap$9.3Blower$10.1Bhigher
Revenue$2.9Bhigher$2.7Blower
Earnings$537.9Mhigher$247.1Mlower
Employees6,000higher5,400lower
Total assets$5.3Bhigher$3.2Blower
Valuation
P/E17.2lower23.7higher
P/S3.2lower3.7higher
P/B1.9lower6.4higher
Dividend yield0.00%0.00%
Profitability
Operating margin16.3%lower17.5%higher
Balance sheet
Net assets$4.6Bhigher$1.5Blower
Total liabilities$729.5Mlower$1.7Bhigher
Total debt—$949.2M
Cash on hand$526.2Mlower$716.1Mhigher
Price change
Today-0.72%lower+0.03%higher
1 year-15.5%higher-56.4%lower

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

Loading the one-year price chart…

Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

Both (0)

None of the tracked investors.

Insulet only (1)

Percentages are each holding's share of that investor's reported portfolio. Who owns GMED · Who owns PODD

Further comparisons

Learn

Questions and answers

Which is bigger, Globus Medical or Insulet?

By market value, Insulet is the larger: $10.1B against $9.3B for Globus Medical. By revenue in its latest fiscal year, Globus Medical is the larger: $2.9B against $2.7B for Insulet.

Which has the higher P/E ratio?

Insulet: 23.7, against 17.2 for Globus Medical. A higher P/E means the market pays more for each dollar of the last twelve months' earnings; on its own it does not say which is the better value.

Which has the higher operating margin?

Insulet: 17.5%, against 16.3% for Globus Medical. Operating margin is operating income as a share of revenue in the latest fiscal year.

Which has the higher dividend yield?

Neither: both stand at 0.00%. Dividend yield is the last twelve months' dividends as a share of today's share price.

Which superinvestors own both Globus Medical and Insulet?

None of the tracked superinvestors holds both in their latest 13F filing. 3 hold Globus Medical and 1 holds Insulet.

Cite this page

Funkfolio, “Globus Medical vs Insulet”, data as of 18 November 2026. https://funkfolio.com/compare/gmed-vs-podd

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.